Trial Profile

A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Garadacimab (Primary)
Indications COVID 2019 infections; COVID-19 pneumonia; Interstitial lung diseases; Respiratory distress syndrome
Focus Therapeutic Use
Sponsors CSL Behring

Most Recent Events

18 Mar 2022 Results of pooled data from PI and PII studies assessing COV PK by utilizing a population PK model presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
19 Jan 2021 Status changed from recruiting to completed.
06 Jul 2020 According to a CSL Behring media release, first patient has been enrolled in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com